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Acupuncture use was nearly six times more common among chiropractic users 
than in the overall population (2.2% vs. 0.37%); similarly, nearly half (42.5%) of 
acupuncture users also had a claim for chiropractic. Over one-in-five patients 
(21.0%) with general joint or back pain used chiropractic, of which 2.65% also 
used acupuncture. CONCLUSIONS: Despite trends suggesting increased use of 
chiropractic and acupuncture, their use remains very low in commercial health 
insurance plans, including patients with inflammation and pain-related 
conditions. While still very low, acupuncture use was more common among 
chiropractic users than in the overall population.  
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OBJECTIVES: To examine the geographic, age and racial variation in the 
prevalence of systemic lupus erythematosus (SLE) in the U.S. veteran population. 
METHODS: Patients diagnosed with SLE (International Classification of Disease 
9thRevision Clinical Modification (ICD-9-CM) diagnosis code 710.0) were included 
in a retrospective study (October 1, 2005 - May 31, 2012) conducted using the 
Veterans Health Administration (VHA) Medical SAS Datasets. Disease prevalence 
was stratified by state, age and race for all the patients, and each category was 
then carefully studied. Descriptive statistics were calculated as means ± 
standard deviation (SD) and percentages to measure the prevalence in the 
sample. RESULTS: A total of 13,257 veterans were diagnosed with SLE in 2011. 
For SLE patients between ages 35 and 54, prevalence was the highest at 0.11%, 
followed by patients age 55 to 64 at 0.07%. Patients age 18-25 and 65+ had SLE 
prevalence of 0.03%, and the median prevalence (0.06%) was observed in patients 
age 26-34. Prevalence by race was also examined: Non-Hispanic Black (0.16%), 
Hispanic (0.07%), Non-Hispanic White (0.05%) and other races (0.04%). 
Geographic variation was examined and the highest SLE prevalence was 
observed in Georgia and Alabama (both 0.11%), followed by Arizona, New 
Hampshire, Maryland, Tennessee, Vermont and Virginia (all 0.08%). 
CONCLUSIONS: There is statistical evidence that middle-aged patients have a 
higher probability to be diagnosed with SLE, and younger and elderly patients 
have a relatively smaller probability. Stratified by race, black, Hispanic and white 
patients were more likely to be diagnosed with SLE compared to other races. 
Statistical results also show that patients living in the Southeastern are of the 
United States had a higher risk of SLE diagnosis.  
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OBJECTIVES: The aim of this study was to evaluate the impact of race on quality 
of anticoagulation control in patients undergoing major orthopedic surgery. 
METHODS: We conducted a retrospective, observational cohort study in an 
inner-city underserved population treated with warfarin thromboprophylaxis 
after total hip replacement (THR) or total knee replacement (TKR), referred to a 
specialized antithrombosis clinic from 1998 to 2009. Significant variables from 
simple linear regression (p < 0.1) were entered in stepwise multivariate logistic 
regression (alpha < 0.05) to evaluate the effect of race on quality of 
anticoagulation control, defined as within-patient proportion of international 
normalized ratio (INR) levels spent in therapeutic range (INR of 2-3 ± 0.2). 
RESULTS: A total of 400 consecutive patients were evaluated. The average age 
was 58.4±12.5, 56% were African-American, and 26% were Hispanic. The average 
length of warfarin therapy was 50±21 days, and the average within-patient 
proportion of INR levels spent in therapeutic range was 39.2±20.5%. African-
Americans (β= -8.59, p < 0.0001) had lower within-patient proportion of INR 
levels spent in therapeutic range compared to non-African-Americans. In 
addition, males (β= -5.17, p = 0.0069), higher warfarin dose (β= -3.13, p <0.0001), 
higher frequency of anticoagulation monitoring visits (β= -1.13, p = 0.0214) and 
non-adherence with warfarin (β= -0.31, p <0.0001) were significantly associated 
with a lower proportion of INR levels in therapeutic range. After controlling for 
age, gender, comorbidities, and significant covariates, the effect of African-
American race remained significant (β= -6.90, p = 0.0001). CONCLUSIONS: In this 
inner-city underserved population treated with warfarin thromboprophylaxis for 
THR and TKR, African-Americans tended to have lower proportion of INR levels 
in therapeutic range than non-African-Americans. Studies are needed to further 
elucidate factors driving substandard anticoagulation control in minority 
patients.  
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OBJECTIVES: Neuropathic pain (NeP) is a pain caused by a lesion or disease of 
the somatosensory nervous system (International Association for the Study of 
Pain – IASP 2011). In many cases NeP is secondary to herpes zoster infection and 
as a complication of diabetes mellitus. This study aimed to assess the budget 
impact of pregabalin in NeP in adult Colombian population. METHODS: A budget 
impact model was developed with a time horizon of 1 year from the social 
perspective (direct and indirect costs included). Cohort contains 155,030 patients 
over 18 years with NeP, according to Colombian prevalence and considers 20% of 
patients have access to medical treatment. Direct costs (drug acquisition, 
medical visits with general practitioners, specialists and emergency visits) and 
indirect costs (disability payments) of managing patients with neuropathic pain 
were estimated from Colombian sources (tariff manuals and pricing rulings). 
Comparators included those locally approved for NeP: pregabalin (150-300 
mg/day) versus duloxetine (60 mg/day). Univariate deterministic and 
probabilistic sensitivity analyses were done. Costs are in 2012 US$. RESULTS: 
Assuming that each comparator had a 100% market share, the average total 
costs of treating NeP patients for 1 year, with the comparators were: pregabalin 
US $132,965,443 (51.7% drug acquisition, 26.4% medical visits and 21.9% indirect 
costs) and duloxetine US $220,883,844 (68.6% drug acquisition, 14.2% medical 
visits and 17.2% indirect costs). Patients taking pregabalin have a lower 
acquisition cost of drugs. CONCLUSIONS: Pregabalin is a favorable alternative for 
the treatment of NeP compared to duloxetine by saving US $567.1 per 
patient/year compared to duloxetine. Colombian stakeholders should consider 
these findings for future decision-making processes.  
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OBJECTIVES: Treating post-surgical patients with opioid and non-opioid 
medications simultaneously can be an effective way to treat pain, minimize 
opioid-associated side-effects, and reduce hospital length of stay (LOS). The 
objective of this exercise was to develop a budget impact model to evaluate the 
economic impact of increased use of multi-modal analgesia following orthopedic 
or abdominal/pelvic surgery in the hospital setting. METHODS: A total of 50,648 
unique patient encounters from a 2009-2012 US electronic health record 
database were evaluated. Patients were segmented into 280 cohorts based on 
surgical procedure (40 unique orthopedic and abdominal/pelvic procedures) and 
NSAID risk factors (7 unique risk groups). Median LOS was calculated for each 
cohort and compared based on analgesia received (opioid-only vs. multi-modal). 
Findings were adjusted to fit the general case of a 250-bed hospital with an 80% 
occupancy rate and performing 3,400 total orthopedic and abdominal/pelvic 
surgeries/year. Median per-day hospital stay costs of $400 and $460 per 
orthopedic and abdominal/pelvic procedure, respectively, were applied. 
RESULTS: Current proportions of patients receiving multi-modal, opioid-only, 
and non-opioid-only therapy were 29.9%, 63.0%, and 7.1%, respectively. Multi-
modal therapy was associated with reduced LOS for 45.2% of cohorts, no change 
in LOS for 41.7% of cohorts, and increased LOS for 13.1% of cohorts. Increasing 
the proportion of patients receiving multi-modal therapy resulted in cost 
savings. Shifting 20% of patients from opioid-only to multi-modal therapy 
resulted in estimated annual savings of $71,526, while shifting 40% of patients in 
this manner reduced costs by $141,317. Conversely, shifting all patients treated 
with multi-modal therapy to opioid-only therapy increased annual costs by 
$105,204. CONCLUSIONS: The model supports the hypothesis that multi-modal 
therapy is associated with reduced LOS and reduced health care costs. While 
currently-available NSAIDs may present their own side-effect risks, NSAIDs with 
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OBJECTIVES: Hemophilia A is a rare, genetic disorder occurring in males and its 
treatment involves infusing clotting factor concentrate (FVIII). Currently, the 
most widely-used FVIII product in China is plasma-derived FVIII. Since plasma-
derived FVIII is sourced from local blood donations, it is associated with an 
increased risk of blood-borne infection. Blood-borne infections can be life-
threatening and have a significant cost on society. The objective of this study 
was to estimate the extra economic burden associated with a potential blood-
borne infection in the hemophilia population of China. METHODS: An outbreak 
of hepatitis C virus (HCV) was used as a real life example of pathogen 
transmission in the Chinese hemophilia population. Decision tree analysis was 
adopted to calculate the expected life-time incremental cost associated with 
treating hemophilia patients infected with HCV. Costs were discounted and 
sensitivity analyses were conducted to test model sensitivity and assumptions. 
RESULTS: Preventing HCV in hemophilia patients is estimated to save an 
approximately 7 years of life per patient. Expected life-time additional treatment 
cost (FVIII cost not included) of a hemophilia patient infected with HCV was 
estimated at 855,341 RMB. Assuming 10% of the registered Chinese hemophilia A 
patients were affected by HCV, preventing HCV infection in these patients would 
have saved an estimated 774 million RMB in total. CONCLUSIONS: This research 
demonstrates the significant potential economic burden of treating hemophilia 
patients infected with a blood-borne pathogen such as HCV, as well as the value 
of utilizing a FVIII product that eliminates the transmission risk of another 
infectious disease similar to the burden associated with HCV.  
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COSTS ASSOCIATED WITH BREAKTHROUGH PAIN IN CANCER PATIENTS: 
FINDINGS FROM THE NATIONAL BREAKTHROUGH PAIN SURVEY  
